With “Discover new ways to improve and extend people’s lines” as its mission, Novartis, a healthcare company founded in 1996 is headquartered in Basel, Switzerland.
Novartis has about 1,23,000 employees and has a product-reach in over 180 countries. Novartis occupies rank 167 in the Fortune Global 500 Companies list, 2015.
An annual revenue $50.387 billion, R & D expenditure of $8.935 billion and a basic EPS of $7.4 have made Novartis the third top pharmaceutical company in the world. Novartis’ commitment to innovation is showcased by the entry of 25 new projects into its portfolio, 37 Ongoing Phase III Programs, 14 major submissions and 14 major approvals, in 2015.
The business areas in which Novartis operates comprises of Pharmaceuticals, Alcon and Sandoz, contributing to 62%, 20% and 18% of annual revenue, respectively. Pharmaceuticals vertical offers innovative and established medicines in verticals like like oncology, neuroscience, retina, immunology and dermatology, respiratory and cardio-metabolic. Alcon caters to a range of eye care medicines under ophthalmic pharmaceuticals and surgical eye care and vision care products as well. Sandoz is the generics division of Novartis, offering retail generics, biopharmaceuticals and oncology injectables and anti-infective. Classification of Entresto, a Heart Failure medicine by Novartis, as “Class 1” under the global guidelines for Heart Failure treatment by specialist cardiovascular US and EU organizations in May 2016 is expected to propel the growth of sales of the drug in the future.